Identification of an HLA-A2-Restricted Epitope Peptide Derived from Hypoxia-Inducible Protein 2 (HIG2)
Creators
- 1. Wakayama Medical University
- 2. OncoTherapy Science Inc.
- 3. Juntendo University
- 4. University of Tokyo
- 5. University of Chicago
Description
We herein report the identification of an HLA-A2 supertype-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2), which is known to be a diagnostic marker and a potential therapeutic target for renal cell carcinoma. Among several candidate peptides predicted by the HLA-binding prediction algorithm, HIG2-9-4 peptide (VLNLYLLGV) was able to effectively induce peptide-specific cytotoxic T lymphocytes (CTLs). The established HIG2-9-4 peptide-specific CTL clone produced interferon-γ (IFN-γ) in response to HIG2-9-4 peptide-pulsed HLA-A*02:01-positive cells, as well as to cells in which HLA-A*02:01 and HIG2 were exogenously introduced. Moreover, the HIG2-9-4 peptide-specific CTL clone exerted cytotoxic activity against HIG2-expressing HLA-A*02:01-positive renal cancer cells, thus suggesting that the HIG2-9-4 peptide is naturally presented on HLA-A*02:01 of HIG-2-expressing cancer cells and is recognized by CTLs. Furthermore, we found that the HIG2-9-4 peptide could also induce CTLs under HLA-A*02:06 restriction. Taken together, these findings indicate that the HIG2-9-4 peptide is a novel HLA-A2 supertype-restricted epitope peptide that could be useful for peptide-based immunotherapy against cancer cells with HIG2 expression.
Files
journal.pone.0085267.pdf
Files
(3.2 MB)
| Name | Size | Download all |
|---|---|---|
|
Article md5:678eebce59441515ccd1f373e19c811a |
747.4 kB | Preview Download |
|
md5:dd6fe47a2af4606db2b5506638e56546
|
2.5 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1371/journal.pone.0085267
- Other
- oai:uchicago.tind.io:10713